NEXTCURE, INC Debt Securities, Available-for-sale, Amortized Cost
NEXTCURE, INC (NXTC) had Debt Securities, Available-for-sale, Amortized Cost of $214.81 million as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-08-05
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $214.81M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $231.53M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $249.90M.
- 2020-09-30: Debt Securities, Available-for-sale, Amortized Cost $267.37M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-06-30 | $214.81M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $231.53M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $249.90M 10-Q · filed 2021-08-05 |
| 2020-09-30 | $267.37M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $282.35M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $293.73M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $300.55M 10-K · filed 2021-03-04 |
| 2019-09-30 | $174.21M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |